Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Dec:37:15333175221104354.
doi: 10.1177/15333175221104354.

A Functional Assessment Tool to Distinguish Controls From Alzheimer's Disease in Lima, Peru

Affiliations

A Functional Assessment Tool to Distinguish Controls From Alzheimer's Disease in Lima, Peru

Nilton Custodio et al. Am J Alzheimers Dis Other Demen. 2022 Jan-Dec.

Abstract

Background: The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale is a versatile functional assessment tool for patients with Alzheimer's disease (ad). We evaluated its performance in controls, Peruvians with MCI or AD.

Methods: A cross-sectional study of older adults attending a neurology institute in Lima (Peru) with mild cognitive impairment (MCI), ad or cognitively healthy. Test-retest reliability (intraclass correlation coefficient, ICC; internal consistency, Cronbach's alpha) and validity were assessed.

Results: We enrolled 276 individuals (ad: 113, MCI: 68, controls: 95) with no age, sex, educational level, and depressive symptom differences. Reliability was ideal (ICC: .996), and Cronbach's alpha was adequate (.937). The ADCS-ADL could not differentiate MCI from controls but did differentiate ad severity. The ADCS-ADL correlated highly with nearly all tools.

Conclusions: The ADCS-ADL scale is reliable in a population with ad in Lima, Peru. Future work may validate a tool for Peruvians with lower educational levels.

Keywords: alzheimer disease; dementia; neurocognitive disorders; peru; validation study.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484-496. DOI: 10.1016/S1474-4422(21)00066-1 - DOI - PMC - PubMed
    1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer’s Dementia. 2011;7:270-279. - PMC - PubMed
    1. Sánchez‐Benavides G, Salvadó G, Arenaza‐Urquijo EM, et al. Quantitative informant‐ and self‐reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE. Alzheimer’s Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12:e12127. doi: 10.1002/dad2.12127 - DOI - PMC - PubMed
    1. Jutten RJ, Dicks E, Vermaat L, et al. Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. Neurobiol Aging. 2019;75:109-116. - PubMed
    1. Suzuki Y, Teruya K, Mochizuki H, Nagasawa A, Kondo T, Shimoda N. Evaluation of activities of daily living/instrumental activities of daily living to accurately determine severity of moderate and severe Alzheimer’s disease: comparison of assessments by receiver operating characteristic curve and discriminant analyses. Dementia and Geriatric Cognitive Disorders Extra. 2019;9:227-235. doi: 10.1159/000500019 - DOI - PMC - PubMed

Publication types